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resistanceAbstract There is limited information of level of drug resistance to first-line and
second line anti-tuberculosis agents in treatment naı¨ve pulmonary tuberculosis
(PTB) patients from the Indian region. Therefore, the present prospective study
was conducted to determine the antimicrobial susceptibility to first-line and second
line anti-TB drug resistance in such patients. Sputum samples from consecutive
treatment naı¨ve PTB cases registered in Lala Ram Sarup (LRS) district, under
RNTCP containing 12 Directly Observed Treatment Centres (DOTS), were enrollediology,
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366 V.P. Myneedu et al.using cluster sampling technology. A total of 453 samples were received from July
2011 to June 2012. All samples were cultured on solid medium followed by drug sus-
ceptibility to first and second line anti-tubercular drugs as per RNTCP guidelines.
Primary multi-drug resistance (MDR) was found to be 18/453; (4.0%). Extensively
drug resistance (XDR) was found in one strain (0.2%), which was found to be resistant
to other antibiotics. Data of drug resistant tuberculosis among treatment naı¨ve TB
patients are lacking in India. The presence of XDR-TB and high MDR-TB in small pop-
ulation studied, calls for conducting systematic multi-centric surveillance across the
country.
ª 2015 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Drug resistance in patients with Mycobacterium
tuberculosis (MTB) infection was witnessed soon
after the introduction of anti-tuberculosis agents
[1]. Disease gained international importance with
outbreaks of multi drug resistant tuberculosis
(MDR-TB) in patients with human immunodefi-
ciency virus (HIV) infection in the United States
and Europe [1]. The MDR-TB is defined as resistance
to rifampicin (RIF) and isoniazid (INH). World-wide
prevalence of MDR-TB among new cases and previ-
ously treated cases is estimated as 3.6% (95% CI:
2.1–5.1%) and 20.2% (95% CI: 13.3–27.2%) respec-
tively [2]. This situation poses grave challenge to
the TB control as prolonged, limited and expensive
treatment options with 10–30% of cases resulting
in treatment failure and death [2]. Last decade
witnessed emergence of extensively drug resis-
tance tuberculosis (XDR-TB) defined as resistance
to any fluoroquinolone (FQ) and at least one of
second-line injectable agents: amikacin (AMK),
kanamycin (KAN), and capreomycin (CAP) among
MDR-TB [3]. Globally, 9.6% (95% CI: 8.1–11%) of
MDR cases are XDR and have already spread over
92 countries [2]. The management of these cases
is even more difficult than MDR-TB as these are
unresponsive to almost all anti-tubercular agents.
Though previous treatment for TB is the stron-
gest risk factor for development of DR-TB,
treatment-naı¨ve patients may also get affected
due to either transmission of resistant strains or
spontaneous mutations. In M. tuberculosis, geneti-
cally encoded drug resistance mutations arise
exclusively through chromosomal mutations,
majority of which are single-nucleotide polymor-
phisms. Spontaneous mutations in Mycobacterium
occur as a consequence of errors that arise during
DNA replication at a rate of one mutation error at
two bases in every 10,000 genome copied. The rate
of mutation is possibly affected by several cellular
and external factors, such as UV irradiation,smoking, anti-retroviral therapy, which are still
under study [4]. With growing burden of DR-TB,
such strains are transmitted from close contacts
to normal population increasingly. Prevalence of
primary drug resistance also serves as an epidemi-
ological indicator to assess the success of the TB
control programme. There is paucity of studies on
primary drug resistance from India with no data
of primary XDR-TB, based on culture and drug sus-
ceptibility testing (DST). Therefore, this prospec-
tive study was systematically designed to
determine the antimicrobial susceptibility to first-
line and second line anti-TB drug resistance among
newly diagnosed pulmonary TB (PTB) cases, in a
district under Revised National Tuberculosis
Control Programme (RNTCP).
2. Methods
2.1. Study design and sampling methodology
Lala Ram Sarup (LRS) district has 12 Directly
Observed Treatment Centres (DOTS) covering pop-
ulation of 0.8 million. The present study, consid-
ered new PTB cases defined as those who have
taken anti-tuberculosis drugs for less than one
month [5], to study the drug resistance in LRS field
area under RNTCP as a prospective operational
research. The required sample size for measuring
the drug resistance was calculated as detailed
below [6].
a. Firstly, total number of new PTB cases registered
in all DOTS centres in the specified district, were
obtained for the previous year to understand the
population from which the samples would be
selected.
b. From information available in the institute, the
expected proportion of resistance for RIF was
about 15–20% of the new PTB cases.
c. The absolute precision was considered as 5%.
d. 95% confidence interval was used for the measured
proportion.
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size
n ¼ NZ2Pð1 PÞ=d2ðN  1Þ þ Z2Pð1 PÞ
where N = population size, n = required sample
size, Z = Z-value (from standard normal distribu-
tion) that corresponds to the desired confidence
level or level of significance is 5% for 95% confi-
dence level, P = expected proportion of resistance
in the target population. From population of about
2000 (N) cases, considering an expected proportion
of 17% (p) with absolute precision as 5% with 95%
confidence level, calculated sample size is 196
which is approximated to 200. Furthermore, clus-
ter sampling was adopted for sample collection
from DOTS centres, which required application of
cluster design effect hence above sample size
was multiplied by two. The sample size derived
at 400 was further increased (to account for
expected 10% loss of samples), to get size of 450.
2.2. Sampling procedure
For selection of 450 patients from all the DOTS cen-
tres under the specified area of LRS institute, thirty
cluster sampling method was adopted. To deter-
mine number of patients per cluster, required total
sample size was divided by the number of clusters,
which was found to be 15 patients. In case of more
than one cluster in a DOTS centre, the number was
multiplied by the size of the cluster to calculate
the total number of patients needed from that
centre.
To avoid any bias in patient selection from any
centre, probability proportion to size cluster tech-
nique was utilized for which, list of all the DOTS
centres along with list of newly diagnosed TB
patients during previous year was obtained
(Table 1). The cumulative total was calculated
for each row (cumulative number for second centre
would be (number in first centre) + (number in sec-
ond centre)), and so on. The total number of
patients diagnosed in the previous year was 1942.
The sampling interval was obtained by dividing
1942 by 30 (1942/30 = 65). A random number was
selected between 0 and 65 from random number
table (30). First cluster was selected at 30, next
cluster was selected by adding 65 to 30. Similarly
clusters were selected by adding 65 in the obtained
number, to total of 30 clusters with each of size 15.
2.3. Clinical details
The PTB was identified based on sputum smear
examination with at least 1 smear positive for
AFB and/or radiographic abnormalities consistentwith active PTB [5]. Clinical information form was
filled at DOTS centres for each recruit to include
age and sex, assess risk factors associated with
PTB, such as smoking, alcohol, malnutrition, dia-
betes, HIV, drug abuse. In addition, clinical symp-
toms of cough with/without expectoration, fever,
breathlessness, hemoptysis, weight loss, chest
pain, diarrhea, loss of appetite, leg pain, weak-
ness, abdominal pain, vomiting, headache and
amenorrhoea were also recorded. The study was
approved by institutes ethics committee
2.4. Sample collection
One overnight and one spot sputum sample was
collected from each patient and submitted to the
laboratory under RNTCP. The laboratory is
National Reference Laboratory (NRL), which is cer-
tified for first and second line DST for MTB by the
Supra National Reference Laboratory, Institute of
Tropical Medicine; Antwerp, Belgium. The labora-
tory caters to national level TB institute of India
and is a DR-TB site for management of MDR-TB
and XDR-TB patients.
2.5. Sample processing
Ziehl–Neelsen smear for detection of acid-fast
bacilli (AFB) was performed for each sample and
reported as per RNTCP guidelines [7]. The samples
were processed by modified Petroffs method of
decontamination using 4% of sodium hydroxide
(NaOH). The pellet obtained was washed twice
before inoculation for culture [8].
2.6. Culture and identification
Each processed sample was cultured on two
Lowenstein-Jensen (LJ) slopes. The cultures were
incubated at 37 C and observed for growth every
week up to a maximum of eight weeks. All the iso-
lates grown were identified as M. tuberculosis by
their slow growth rate, colony morphology, smear
microscopy from cultures and inability to grow on
L-J media containing p-nitrobenzoic acid (PNB,
500 lg/ml) [8].
2.7. Drug susceptibility testing
All culture positive samples having sufficient
growth for the preparation of inoculum were
subjected to drug susceptibility testing (DST) for
1st line and 2nd line anti-tubercular drugs
using the modified 1% proportion method on LJ
medium [8]. The antibiotics (Sigma) included four
1st line anti-tubercular drugs, streptomycin; STR
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Table 1 The distribution of the selected clusters from Directly Observed Treatment Centres (DOTS) in Lala Ram Sarup
(LRS) district.
No. Centre Number of
patients
Cumulative
frequency
number
Cluster interval
(1942/30 = 65)
Number of
clusters
Patient
sample size
1 Khanpur 211 211 30, 95, 160 3 45
2 Sangam Vihar J 157 368 225, 290, 355 3 45
3 Sangam Vihar I 170 538 420, 485 2 30
4 Sangam Vihar G 181 719 550, 615, 680 3 45
5 Sangam Vihar K2 192 911 745, 810, 875 3 45
6 Tigri 163 1074 940, 1005, 1070 3 45
7 Mehrauli 191 1265 1135, 1200, 1265 3 45
8 Lala Ram Sarup 184 1449 1330, 1395 2 30
9 Fatehpur 101 1550 1460, 1525 2 30
10 Chattarpur 122 1672 1590, 1655 2 30
11 Jonapur 62 1734 1720 1 15
12 Ber Sarai 208 1942 1785, 1850, 1915 3 45
1942 1942 30 450
368 V.P. Myneedu et al.(4 lg/ml), INH (0.2 lg/ml), RIF (40 lg/ml), etham-
butol; ETB (2 lg/ml) and seven 2nd line drugs, KAN
(30 lg/ml), ethionamide; ETH (40 lg/ml),
cycloserine; CYL (40 lg/ml), ofloxacin; OFL
(2 lg/ml), para-amino salicylic acid; PAS
(1 lg/ml), CAP (40 lg/ml) and AMK (40 lg/ml).
The results were finalized on 42nd day as per the
protocol. Any strain with 1% (the critical propor-
tion) of bacilli resistant to any of the antibiotics,
was classified as resistant to that drug.
2.8. Data analysis
Cluster sampling methodology was used to deter-
mine the clusters as explained above. The percent-
age proportion was adopted to determine the
percentage of drug resistance.
3. Results
During period of July 2011 to June 2012, 453 newly
diagnosed PTB cases were enrolled in this study.
Age ranged from 10 year to 85 year old with median
age being 27. Maximum patients were in the age
group of 15–24 years (158). Overall, males pre-
dominated with ratio of males to females being
1.7:1. Females were commoner in the paediatric
age group of 0–14 years of age (ratio 1.9:1)
(Fig. 1). Of the 453 patients enrolled, 62.3% had
no known risk factors. Smoking was found to be
the commonest risk factor. The HIV positive
patients formed 3.8% of the study group. Two per-
cent of patients were found to be diabetics (Fig. 2).
Commonest clinical symptoms reported by the
recruits are depicted in Fig. 3. Maximum patientscomplained of fever (80.8%), weight loss (79.9%)
and cough with expectoration (79.7%).
Of the sputum collected from 453 patients, 107
(23.6%) patients were smear negative, and 346
(76.4%) were smear positive. The smear positives
included scanty positives 28/346 (8.1%), 1+;
126/346 (36.4%), 2+; 74/346 (21.4%) and 3+;
118/346 (34.1%). Of the total cases, 399/453 (88%)
samples, at-least one LJ culture was positive for
MTB. Nine (2.0%) cultures got contaminated. Total
of 36 sampleswere both smear and culture negative,
333 samples were both smear and culture positive,
66 sampleswere smear negative and culture positive
and 9 were smear positive and culture negative.
Out of the 399 cultures positives, DST was per-
formed on 340 isolates with sufficient growth
(more than 20 colonies) as is required for inoculum
preparation to put solid culture DST. Among first
line antibiotics tested, 261/340 (76.8%) cases were
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(1.5%) cases were resistant to all four first line
antibiotics. The resistance to any three first-line
antibiotics was seen in 9/340 (2.6%) cases, all being
resistant to STR, INH and RIF. Eighteen; (5.6%) iso-
lates were found to be MDR. None of the patients
were found to be only ethambutol resistant. None
of the MDR patients were known as HIV positive.
Among the MDR cases, two (11.1%) were children,
both being female and one (5.5%) was male in the
geriatric age group. Mono-INH resistance was found
in 24 (7.1%) of isolates and mono-RIF resistance
was found in 3(0.9%) of isolates. Among all cases
enrolled (453), MDR prevalence was 4.0%.
Antibiotic resistance pattern for first-line antibi-
otics is detailed in Table 2.
Among second line antibiotics tested, 305
(89.7%) isolates were sensitive to all the four
antibiotics whereas 1 (0.3%) isolate was resistantto all six second line antibiotics tested. The XDR
prevalence was found to be 0.2% among all 453
patients enrolled. The details of resistance rates
(%) observed against 2nd line drugs are shown in
Table 3.
4. Discussion
The present prospective study depicts the drug
resistance to first line and second line anti-
tubercular drugs among treatment naı¨ve PTB
patients of LRS district in New Delhi. The DOTS
centres within the LRS district caters mainly to
urban slums comprising of low socio-economic
group. Though less, in the district most patients
referred from private sector and various non gov-
ernment organizations in the area, were included.
The sampling has been done systematically as per
the standard guidelines [6]. During the study
Table 3 Drug susceptibility pattern of Mycobacterium tuberculosis to second line anti-tubercular agents.
Second line anti-tubercular agents Number Percentage
All sensitive 305 89.70
Kanamycin 1 0.30
Ethionamide 5 1.50
Ofloxacin 9 2.60
PAS 6 1.80
Capreomycin 1 0.30
Kanamycin + PAS 1 0.30
Ethionamide + ofloxacin 2 0.60
Ethionamide + PAS 3 0.90
Ofloxacin + PAS 2 0.60
Capreomycin + PAS 1 0.30
Kanamycin + PAS + capreomycin 1 0.30
Ethionamide + ofloxacin + PAS 1 0.30
Ofloxacin + capreomycin + PAS 1 0.30
Kanamycin + PAS + capreomycin + ethionamide + ofloxacin + amikacin 1 0.30
Total 340 100
Table 2 Drug susceptibility pattern of Mycobacterium tuberculosis to first line anti-tubercular agents.
First line anti-tubercular agents Number Percentage
All sensitive 261 76.80
Streptomycin 19 5.60
Isoniazid 24 7.10
Rifampicin 3 0.90
Streptomycin + isoniazid 14 4.10
Streptomycin + rifampicin 1 0.30
isoniazid + rifampicin 4 1.20
Streptomycin + isoniazid + rifampicin 9 2.60
Streptomycin + isoniazid + rifampicin + ethambutol 5 1.50
Total 340 100
370 V.P. Myneedu et al.period, one morning and one spot sputum sample
from 453 patients were received from these
patients.
We found males to be predominant in our study
with 63.6%. This finding is also seen in many other
studies [5–9]. As this population constitutes an
economically productive section of society, the
presence of disease in this segment has far reach-
ing socio-economic implications. Pressure to con-
tinue working in-spite of poor health could lead
to decreased compliance toward regular medica-
tion thereby increasing the threat of developing
drug resistance.
Most PTB cases were not associated with any risk
factor. Among the risk factors found, smoking was
found to be the commonest. Association of TB with
smoking is well established as reported in earlier
studies [10]. Impaired immunity is also associated
with high incidence of TB. The lifetime risk of TB
in immuno-competent persons is 5–10% but in
HIV-positive individuals, there is 5–15% annual riskof developing active TB disease [11]. Impaired
immunity is also seen in diabetes mellitus, a meta-
bolic disorder. India accounts for 1/5th of worlds
newly diagnosed TB of which almost 50% are dia-
betics [11]. In the present study, 3.8% and 2.0%
of PTB patients were found to be HIV positive and
diabetics respectively.
Commonest symptoms reported by the patients
enrolled in the study included fever (80.8%), weight
loss (79.9%) and cough with expectoration (79.7%),
which are known in PTB patients. Surprisingly, 40%
patients only complained of loss of appetite.
Appetite-regulatory hormones are altered in TB
patients, which improve on treatment [12].
Among newly diagnosed PTB patients, 76.4%
were found to be smear-positive. World-wide
around 56% of new cases of PTB are sputum smear
positive tuberculosis [2]. Culture provided an
incremental microbiological confirmation of 14.6%
among the smear negatives which is less than
expected. This could be because of use of harsher
Table 4 Indian studies on prevalence of primary multi-drug resistant tuberculosis in India.
Authors Year of
publication
& place
Study setting Study design Sample size MDR rate (%) Refs.
Present study 2011–12 New Delhi, India Lala Ram Sarup District with 12 Designated
Microscopy Centres. Population of 0.8 million
Drug resistance estimation to first and
second line anti-tubercular agents
among new cases
450 4.00
Sharma et al. 2008–2009 New Delhi, India Designated Microscopy Centre at Sanjay
Gandhi Memorial Hospital
Drug resistance estimation to first line
anti-tubercular agents among sputum
positive cases
218 1.10 [5]
DSouza et al. 2004–7 Mumbai, India Four central wards in Mumbai with high
sputum-positive case load. Population 3
million
Levels of drug resistance to first line
anti-tubercular agents in new and first
line treatment-failure cases
493 24 [13]
Joseph et al. 2006 Kerala, India Ernakulam District Level of drug resistance to first line anti-
tubercular agents among new smear-
positive pulmonary tuberculosis cases
344 2 [14]
Ramachandran et al. 2005 Gujarat, India State of Gujarat. 56 million population Drug resistant survey to first and second
line anti-tubercular agents on
representative samples of new and
previously treated pulmonary TB
1571 2.40 [15]
Paramasivan et al. 2002 Tamil Nadu & Karnataka, India 23 centres in North Arcot district and 20
centres in Raichur district
Levels of drug resistance to first line
anti-tuberculars and ofloxacin in new and
previously treated cases of pulmonary TB
320, 314 3 [16]
Jain et al. 2000–2, Lucknow, India One Primary Level Centre and one District
Tuberculosis Centre and One Tertiary Centre
Hospital
Prevalence of multi-drug resistance in
three different levels of health care
1014 13.20 [17]
Jain et al. 1990–91, New Delhi, India Intermediate Reference Laboratory Retrospective study of drug resistance
levels to first line anti-tubercular agents
in new and previously treated
NA 0.60 [18]
NA: not available.
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372 V.P. Myneedu et al.decontamination using modified Petroffs method,
recommended by RNTCP. Two percent of smear
positives were culture negative and only 2.0% of
total cultures got contaminated which is as per
the acceptable standards [8].
The prevalence of MDR in our study from a
RNTCP New Delhi among treatment naı¨ve patients
was found to be 4.0% which is higher than expected
national average of 2.2% [2]. Treatment naı¨ve MDR
rates as reported by Indian studies from various
regions, over the years ranged from 0.6% to 24%
as detailed in Table 4 [5,13–18]. The high rate
could be because most of the population is mainly
from urban slums, i.e. low-socio economic back-
ground with over-crowded houses, lack of ventila-
tion and poor hygiene. Much higher rates were
found in studies from Lucknow and Mumbai, with
treatment naı¨ve MDR-TB to be 13.2% and 24%
respectively. These studies had potential bias in
the patient selection as the retreatment cases
could not be fully excluded leading to high MDR
rate. The high treatment naı¨ve MDR-TB rate brings
about the significance of applying newer rapid TB
diagnostics such as Xpert and other nucleic acid
assays in both private and public health systems
in the region. Mathematical modelling studies have
suggested the implementation of newer TB diag-
nostics and rapid DST methods, as these are cost
effective alternatives in high burden settings that
reduce spread of TB and DR-TB [19].
The XDR prevalence among all enrolled cases
was found to be 0.2% with one isolate being XDR.
This strain was resistant to other first line and sec-
ond line antibiotics as well. The isolate belonged to
a 64 year old adult male, HIV negative with history
of diabetes. Presently, there are no data available
on the prevalence of XDR among the newly diag-
nosed TB patients from any region of India.
However few studies have reported XDR rates in
previously treated TB patients ranging from 1.5%
to 22.2% [20–24]. Worldwide, 6.7–11.2% of MDR
cases are found as XDR [2]. Such patients are usu-
ally treatment failures to the available regimens.
The transmission of primary XDR has been reported
in South Africa, among HIV positive patients [25].
In India, facility for performing second line anti-
tubercular DST is limited to few advanced labora-
tories, which contemplate detection of resistance
to second line usually when patient is XDR-TB sus-
pect. Besides, most such laboratories are not certi-
fied or accredited leading to paucity of authentic
and validated drug susceptibility data [24].
This study has some limitations as, in spite of
generating useful data of primary MDR-TB and
XDR-TB prevalence in a RNTCP district, may notbe representative of the whole country. A drug
surveillance survey comprising RNTCP centres from
different regions of the country, inclusive of pri-
vate practitioners, is possibly warranted. The study
also could not capture rural population as the area
covered caters mainly to urban slums which are
epidemiologically different.
5. Conclusion
To the best of our knowledge, this is the first sys-
tematic study from a district under RNTCP in
India of determination of both MDR-TB and XDR-
TB among treatment naı¨ve TB cases. The high
MDR-TB and XDR-TB in the small population stud-
ied, warrants accurate nation-wide multi-centric
drug resistance surveillance in the country. Given
the high level of MDR-TB, its rapid detection using
WHO approved newer modalities for all diagnosed
cases in the country, may be considered.
Furthermore, setting up of more certified or
accredited laboratories for diagnosis of any DR-TB
is significant in ensuring accurate diagnosis of the
condition. This in turn would determine accurate
treatment of the patient eventually leading to
decreased spread of DR-TB in the community and
therefore control of the disease.
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